Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
Authors:
- 3 March 2023
- journal article
- research article
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 11 (4) , 233-241
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 25 references indexed in Scilit:
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational studyDiabetes, Obesity and Metabolism, 2018
- Factors Contributing to Increases in Diabetes-Related Preventable Hospitalization Costs Among U.S. Adults During 2001–2014Diabetes Care, 2018
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017Cardiovascular Diabetology, 2018
- Economic Costs of Diabetes in the U.S. in 2017Diabetes Care, 2018
- DECLARE‐TIMI 58: Participants’ baseline characteristicsDiabetes, Obesity and Metabolism, 2018
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- A New Equation to Estimate Glomerular Filtration RateAnnals of Internal Medicine, 2009